XML 58 R42.htm IDEA: XBRL DOCUMENT v3.3.1.900
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]  
Summary of Components of Rent Expense

The table below summarizes the components of rent expense for the fiscal year ended December 31, as follows:

 

     2015      2014      2013  

Rent expense

   $ 1,844,610       $ 1,955,747       $ 2,612,899   

Sublease income

     —          —          (53,726
  

 

 

    

 

 

    

 

 

 

Rent expense, net

   $ 1,844,610       $ 1,955,747       $ 2,559,173   
  

 

 

    

 

 

    

 

 

 
Future Minimum Payments Under All Leases and Loan Payable

Future minimum payments under all leases and loan payable at December 31, 2015 are as follows:

 

     Loan
Payable SVB
     Capital
Leases
     Operating
Leases
 

2016

   $ 1,440,679       $ 20,670       $ 1,968,459   

2017

     —          11,202         2,014,706   

2018

     —          4,913        2,061,260   

2019

     —          —          2,108,130   

2020

     —          —          2,155,325   

Thereafter

     —          —          3,933,455   
  

 

 

    

 

 

    

 

 

 

Total minimum lease and loan payments (1)

     1,440,679         36,785       $ 14,241,335   
        

 

 

 

Less amounts representing interest

     18,184         875      
  

 

 

    

 

 

    

Principal amounts of loan payable and capital lease obligations

     1,422,495         35,910      

Less current maturities

     1,422,495         20,032      
  

 

 

    

 

 

    

Loan payable and capital lease obligations, less current maturities

   $ —        $ 15,878      
  

 

 

    

 

 

    

 

(1) An aggregate of approximately $9.2 million of principal and accrued interest under the CIRM Loan Agreement is not included. In April 2013, we entered into an agreement with the CIRM under which CIRM would have provided up to approximately $19.3 million as a forgivable loan, in accordance with mutually agreed upon terms and conditions and CIRM regulations. The CIRM loan was to have helped fund preclinical development of our HuCNS-SC cells for Alzheimer’s disease. Between July 2013 and August 2014, we received in aggregate, approximately $9.6 million as disbursements of the loan provided under the CIRM Loan Agreement. However in December 2014, as findings under this pre-clinical study in Alzheimer’s disease did not meet pre-determined criteria for ongoing funding for this program by CIRM, we decided to wind down this pre-clinical study which had been funded in part by the CIRM loan agreement. Under the terms of the CIRM loan agreement, principal amount of approximately $8,917,000 and accrued interest of approximately $243,000 were forgiven. However, authoritative accounting guidance requires certain conditions (which includes a legal release from the creditor) to be met before a liability can be extinguished and derecognized. In February 2015, we repaid CIRM approximately $679,000 of the aggregate loan proceeds received.